Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Seliger

Showing results (231-240 of 304) with videos related to

Pageof 31
Sort By:
Cancers|August 7, 2021
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant MelanomaStefanie Meyer, Diana Handke, Anja Mueller, et al.
Urologic Oncology|September 2, 2018
Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinomaAndré Steven, Sandra Leisz, Sebastian Fussek, et al.
Cell Death Discovery|September 26, 2021
Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibitionDavid Junk, Sebastian Krämer, Johannes Broschewitz, et al.
International Journal of Cancer|July 8, 2010
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumorKatrin Singer, Michael Kastenberger, Eva Gottfried, et al.
Oncoimmunology|March 24, 2025
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patientsLe Tong, Veronika Kremer, Shi Yong Neo, et al.
International Journal of Cancer|August 18, 2010
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2Kousaku Mimura, Takashi Ando, Isabel Poschke, et al.
Plos One|October 7, 2015
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer CellsRiki Okita, Diana Wolf, Koichiro Yasuda, et al.
Cancer Immunology, Immunotherapy : CII|August 4, 2019
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapyMichael Friedrich, Simon Jasinski-Bergner, Maria-Filothei Lazaridou, et al.
Journal of Translational Medicine|March 7, 2025
Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancersKarthikeyan Subbarayan, Helena Bieber, Chiara Massa, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificityAdi Reches, Yael Ophir, Natan Stein, et al.
Pageof 31

Showing results (231-240 of 304) with videos related to

Sort By:
Pageof 31
Cancers|August 7, 2021
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant MelanomaStefanie Meyer, Diana Handke, Anja Mueller, et al.
Urologic Oncology|September 2, 2018
Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinomaAndré Steven, Sandra Leisz, Sebastian Fussek, et al.
Cell Death Discovery|September 26, 2021
Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibitionDavid Junk, Sebastian Krämer, Johannes Broschewitz, et al.
International Journal of Cancer|July 8, 2010
Warburg phenotype in renal cell carcinoma: high expression of glucose-transporter 1 (GLUT-1) correlates with low CD8(+) T-cell infiltration in the tumorKatrin Singer, Michael Kastenberger, Eva Gottfried, et al.
Oncoimmunology|March 24, 2025
Cellular and secretome profiling uncover immunological biomarkers in the prognosis of renal cell carcinoma patientsLe Tong, Veronika Kremer, Shi Yong Neo, et al.
International Journal of Cancer|August 18, 2010
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2Kousaku Mimura, Takashi Ando, Isabel Poschke, et al.
Plos One|October 7, 2015
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer CellsRiki Okita, Diana Wolf, Koichiro Yasuda, et al.
Cancer Immunology, Immunotherapy : CII|August 4, 2019
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapyMichael Friedrich, Simon Jasinski-Bergner, Maria-Filothei Lazaridou, et al.
Journal of Translational Medicine|March 7, 2025
Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancersKarthikeyan Subbarayan, Helena Bieber, Chiara Massa, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificityAdi Reches, Yael Ophir, Natan Stein, et al.
Pageof 31